Logo

American Heart Association

  1
  0


Final ID: WMP67

Circadian Variation In Collateral Status: The HERMES Collaboration

Abstract Body: Background
Prior studies have demonstrated that the incidence of stroke and rate of infarct progression varies across the 24-hour cycle and that circadian rhythm is associated with the brain’s response to reperfusion and neuroprotection. However, the pathophysiology of this variation is poorly understood. In this study we assessed changes in collateral status with time of day as a possible mechanism behind this variation.

Methods
Using data from the 7 randomized EVT trials in the HERMES collaboration, patients with analyzable baseline CT angiograms were selected. Presenting collateral status on CTAs was rated using the Regional Collateral Score (rCS). The effect of time of onset (last known well) and time of scan on collateral status was assessed. Time of day was analyzed as: 1) binary day-night (23:00–06:59/07:00–22:59); 2) 4-hour intervals (23:00–02:59/03:00–06:59/07:00–10:59/11:00–14:59/15:00–18:59/19:00–22:59) and 3) a continuous variable as per Consortium International pour la Recherche Circadienne sur l’AVC recommendations.

Results
Among 1250 patients with LVOs, 1086 (86.9%) had daytime and 164 (13.1%) had night-time stroke onset. Baseline demographic and clinical features of patients that differed (Table 1) were night-time onset patients were younger (62.0 vs 67.1 years), less often had highly severe (NIHSS>16) deficits (43.6% vs 56.3%), had longer onset-to-arrival (186 vs 122 minutes), and longer onset-to-imaging (218 vs 159 minutes). In multivariable analysis, categorizing based on last known well time, there were no significant difference in rCS score by night vs day (7.5±2.0 vs 7.4±2.3 p=0.99) or by 4-hour intervals (7.8±1.9 vs 7.3±2.1 vs 7.4±2.2 vs 7.5±2.2 vs 7.5±2.3 vs 7.1±2.4 p=0.24) (Figure 1). Similarly, categorizing by scan time, there were no significant differences in rCS score by night vs day (7.3±2.3 vs 7.4±2.2 p=0.60) or by 4-hour intervals (7.2±2.4 vs 7.6±2.0 vs 7.3±2.2 vs 7.4±2.1 vs 7.5±2.3 vs 7.6±2.3 p=0.22) (Figure 1). The relationship between continuous time and rCS mapped by LOESS regression also did not indicate substantial rCS variation with time of onset (Figure 2).

Conclusion
Our study does not demonstrate a strong relationship between time of day and regional collateral score. This was at least partially driven by a ceiling effect as most patients had good collateral scores. Further studies to identify patient and imaging characteristics that may explain the relationship between circadian variation of stroke outcomes are needed.
  • Tariq, Muhammad Bilal  ( University of Alabama at Birmingham , Birmingham , Alabama , United States )
  • Jovin, Tudor  ( Cooper Neurological Institute , Haddonfield , New Jersey , United States )
  • Mitchell, Peter  ( The Royal Melbourne Hospital, University of Melbourne , Parkville , Victoria , Australia )
  • Campbell, Bruce  ( The Royal Melbourne Hospital, University of Melbourne , Parkville , Victoria , Australia )
  • Bracard, Serge  ( CHRU Nancy , Nancy , France )
  • Guillemin, Francis  ( CHRU Nancy , Nancy , France )
  • Muir, Keith  ( UNIVERSITY OF GLASGOW , Glasgow , United Kingdom )
  • White, Phil  ( Newcastle University , Newcastle , United Kingdom )
  • Dippel, Diederik  ( ERASMUS MC , Bunnik , Netherlands )
  • Hill, Michael  ( University of Calgary , Calgary , Alberta , Canada )
  • Goyal, Mayank  ( University of Calgary , Calgary , Alberta , Canada )
  • Brown, Scott  ( BRIGHT Research Partners , Mooresville , North Carolina , United States )
  • Saver, Jeffrey  ( David Geffen School of Medicine, University of California Los Angeles , Los Angeles , California , United States )
  • Liebeskind, David  ( David Geffen School of Medicine, University of California Los Angeles , Los Angeles , California , United States )
  • Tiedt, Steffen  ( ISD , Munich , Germany )
  • Lun, Ronda  ( Stanford University Medical Center , Stanford , California , United States )
  • Albers, Gregory  ( Stanford University Medical Center , Stanford , California , United States )
  • Mun, Katherine  ( David Geffen School of Medicine, University of California Los Angeles , Los Angeles , California , United States )
  • Majoie, Charles  ( AMC , Amsterdam , Netherlands )
  • Demchuk, Andrew  ( University of Calgary , Calgary , Alberta , Canada )
  • Author Disclosures:
    Muhammad Bilal Tariq: DO NOT have relevant financial relationships | Tudor Jovin: DO have relevant financial relationships ; Ownership Interest:Route92:Active (exists now) ; Ownership Interest:Viz.ai:Active (exists now) ; Consultant:Contigo Medical:Active (exists now) ; Research Funding (PI or named investigator):Stryker:Past (completed) ; Research Funding (PI or named investigator):Medtronic:Past (completed) ; Consultant:Johnson&Johnson :Active (exists now) ; Ownership Interest:NTI:Active (exists now) ; Ownership Interest:Basking :Active (exists now) ; Ownership Interest:Galaxy:Active (exists now) ; Ownership Interest:Kandu:Active (exists now) ; Ownership Interest:AptaTargets:Active (exists now) ; Ownership Interest:Anaconda:Active (exists now) ; Ownership Interest:Methinks:Active (exists now) ; Ownership Interest:FreeOx Biotech:Active (exists now) | Peter Mitchell: DO have relevant financial relationships ; Research Funding (PI or named investigator):Stryker:Past (completed) ; Speaker:Microvention:Past (completed) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) | Bruce Campbell: DO NOT have relevant financial relationships | Serge Bracard: DO NOT have relevant financial relationships | francis guillemin: DO NOT have relevant financial relationships | Keith Muir: DO have relevant financial relationships ; Consultant:Boehringer Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Past (completed) ; Speaker:Brainomix:Past (completed) ; Speaker:Boehringer Ingelheim:Past (completed) ; Consultant:Woolsey Pharma:Active (exists now) ; Consultant:Abbvie:Active (exists now) ; Consultant:Brainomix:Active (exists now) ; Consultant:Hyperfine:Active (exists now) | Phil White: No Answer | Diederik Dippel: DO NOT have relevant financial relationships | Michael Hill: DO have relevant financial relationships ; Consultant:Brainsgate Inc:Past (completed) ; Individual Stocks/Stock Options:Circle Inc:Active (exists now) ; Individual Stocks/Stock Options:Basking Bioscience:Active (exists now) ; Research Funding (PI or named investigator):Boehringer-Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) ; Consultant:Diamedica Inc:Active (exists now) | Mayank Goyal: DO have relevant financial relationships ; Consultant:Medtronic:Active (exists now) ; Ownership Interest:Circle:Active (exists now) ; Research Funding (PI or named investigator):Cerenovus:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) ; Advisor:Fluid Biomed:Active (exists now) ; Consultant:Mentice:Active (exists now) ; Consultant:Microvention:Active (exists now) | Scott Brown: No Answer | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Viz.ai:Active (exists now) ; Individual Stocks/Stock Options:Let's Get Proof:Active (exists now) ; Individual Stocks/Stock Options:Neuronics:Active (exists now) ; Consultant:Genentech:Expected (by end of conference) ; Consultant:Roche:Active (exists now) ; Consultant:Novo Nordisc:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:BrainQ:Active (exists now) ; Consultant:Medtronic:Active (exists now) | David Liebeskind: DO NOT have relevant financial relationships | Steffen Tiedt: DO NOT have relevant financial relationships | Ronda Lun: No Answer | Gregory Albers: DO have relevant financial relationships ; Consultant:iSchemaView:Active (exists now) ; Individual Stocks/Stock Options:iSchemaView:Active (exists now) ; Consultant:Genentech:Past (completed) | Katherine Mun: DO NOT have relevant financial relationships | Charles Majoie: DO have relevant financial relationships ; Individual Stocks/Stock Options:Nicolab:Active (exists now) ; Research Funding (PI or named investigator):European Commission:Active (exists now) ; Research Funding (PI or named investigator):Boehringer-Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Stryker:Active (exists now) | Andrew Demchuk: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Imaging Moderated Poster Tour I

Wednesday, 02/05/2025 , 06:00PM - 07:00PM

Moderated Poster Abstract Session

More abstracts on this topic:
More abstracts from these authors:
Association between Time and Severe Hypoperfusion with Risk of Hemorrhagic Transformation in Thrombectomy Stroke Patients

Pensato Umberto, Goyal Mayank, Demchuk Andrew, Hill Michael, Ospel Johanna

Modified Rankin Score at 90 Days vs. NIH Stroke Scale at 24 Hours as Primary Outcome in Acute Stroke Trials

Ospel Johanna, Dippel Diederik, Majoie Charles, Jovin Tudor, Campbell Bruce, Mitchell Peter, Bracard Serge, Guillemin Francis, Hill Michael, Goyal Mayank, Brown Scott, Bosshart Salome, Stebner Alexander, Uchida Kazutaka, Demchuk Andrew, Saver Jeffrey, White Phil, Muir Keith

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)